Recruiting
Phase 2

Study of Olutasidenib and Temozolomide in HGG

Sponsor:

Rigel Pharmaceuticals

Code:

NCT06161974

Conditions

High Grade Glioma

Astrocytoma

Astrocytoma, Grade III

Astrocytoma, Grade IV

Diffuse Intrinsic Pontine Glioma

Eligibility Criteria

Sex: All

Age: 12 - 39

Healthy Volunteers: Not accepted

Interventions

Olutasidenib + TMZ

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Rigel Pharmaceuticals on 2025-03-25.